Lyndra Therapeutics

[Not Yet Scheduled]
Lyndra Therapeutics is pioneering long-acting oral therapies, the most significant advance in oral drug delivery in decades. Lyndra’s proprietary LYNX™ drug delivery platform delivers medicine for a week or longer in an oral form.

Lyndra’s story began in 2015 with revolutionary technology that emerged from the Langer Lab at MIT, where the company was founded to develop, expand and eventually commercialize the technology that would ultimately become the LYNX™ drug delivery platform. In its first six years, Lyndra has achieved rapid progress, formulating 19 therapies in the lab and advancing four therapeutic products to the clinic, validating the feasibility of its platform with multiple APIs.

Thanks to more than $240 million raised to date from investors and partners, Lyndra has advanced the LYNX™ drug delivery platform, prepared oral weekly risperidone (LYN-005) for pivotal trials and opened a custom-built GMP manufacturing facility in Lexington, MA.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Massachusetts
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
LYN-005 (once weekly risperidone)
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
6